UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeostasis by targeting PGC1β in hepatocellular carcinoma

The treatment for hepatocellular carcinoma (HCC) is promising in recent years, but still facing critical challenges. The first targeted therapy, sorafenib, prolonged the overall survival by months. However, resistance often occurs, largely limits its efficacy. Sorafenib was found to target the elect...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Signal Transduct Target Ther
Autors principals: Xu, Junjie, Ji, Lin, Ruan, Yeling, Wan, Zhe, Lin, Zhongjie, Xia, Shunjie, Tao, Liye, Zheng, Junhao, Cai, Liuxin, Wang, Yifan, Liang, Xiao, Cai, Xiujun
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8129126/
https://ncbi.nlm.nih.gov/pubmed/34001851
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41392-021-00594-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars